These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

464 related items for PubMed ID: 24661317

  • 1. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
    Vanneste L, Wolter P, Van den Oord JJ, Stas M, Garmyn M.
    J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):61-8. PubMed ID: 24661317
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study.
    Chu EY, Wanat KA, Miller CJ, Amaravadi RK, Fecher LA, Brose MS, McGettigan S, Giles LR, Schuchter LM, Seykora JT, Rosenbach M.
    J Am Acad Dermatol; 2012 Dec; 67(6):1265-72. PubMed ID: 22609219
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks.
    Anforth R, Carlos G, Clements A, Kefford R, Fernandez-Peñas P.
    Br J Dermatol; 2015 Jan; 172(1):239-43. PubMed ID: 25040674
    [Abstract] [Full Text] [Related]

  • 12. Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma.
    Dika E, Patrizi A, Ribero S, Fanti PA, Starace M, Melotti B, Sperandi F, Piraccini BM.
    Eur J Dermatol; 2016 Jun 01; 26(3):232-9. PubMed ID: 27019511
    [Abstract] [Full Text] [Related]

  • 13. A comparative study of the cutaneous side effects between BRAF monotherapy and BRAF/MEK inhibitor combination therapy in patients with advanced melanoma: a single-centre experience.
    Russo I, Zorzetto L, Frigo AC, Chiarion Sileni V, Alaibac M.
    Eur J Dermatol; 2017 Oct 01; 27(5):482-486. PubMed ID: 29084636
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. BRAF Inhibitor-Induced Antitumoral Granulomatous Dermatitis Eruption in Advanced Melanoma.
    Garrido MC, Gutierrez C, Riveiro-Falkenbach E, Ortiz P, Rodriguez-Peralto JL.
    Am J Dermatopathol; 2015 Oct 01; 37(10):795-8. PubMed ID: 26381028
    [Abstract] [Full Text] [Related]

  • 16. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations.
    Sinha R, Larkin J, Gore M, Fearfield L.
    Br J Dermatol; 2015 Oct 01; 173(4):1024-31. PubMed ID: 26109403
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Tumor-free osteosclerotic lesions in patients treated for metastatic melanoma using BRAF inhibitors.
    Bottlaender L, Perier-Muzet M, Lapras V, Thomas L, Dalle S.
    Melanoma Res; 2017 Feb 01; 27(1):68-71. PubMed ID: 27759578
    [Abstract] [Full Text] [Related]

  • 20. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.
    Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, Hamid O, Infante JR, Millward M, Pavlick AC, O'Day SJ, Blackman SC, Curtis CM, Lebowitz P, Ma B, Ouellet D, Kefford RF.
    Lancet; 2012 May 19; 379(9829):1893-901. PubMed ID: 22608338
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.